Want to see AU:CMP full AI Analyst Report?
Compumedics Limited (CMP) AI Stock Analysis
Top Page
Compumedics Limited
(ASX:CMP)
The overall score reflects a company in recovery with improving revenue, margins, and cash flows but still fragile profitability and volatile results as the primary driver. A mildly constructive technical picture adds some support without indicating strong momentum. These positives are offset by an extremely demanding valuation and lack of dividend income, which cap the score and highlight elevated risk if operational progress stalls.
Compumedics Limited (CMP) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 47.94M
- Dividend Yield
- ―
- Average Volume (3M)
- 67.59K
- Price to Earnings (P/E)
- 218.2
- Beta (1Y)
- 0.87
- Revenue Growth
- 18.54%
- EPS Growth
- ―
- Country
- Australia
- Employees
- 175
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Compumedics Limited Business Overview & Revenue Model
Company Description
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region,...
Compumedics Limited Financial Statement Overview
Summary
Financial performance shows a clear turnaround with solid revenue growth, consistently strong gross margins above 50%, improved EBIT/EBITDA and cash generation, but profitability remains very thin and earnings and cash flows are still volatile.
Income Statement
58NeutralBalance Sheet
60NeutralCash Flow
68Positive| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.25M | 60.25M | 51.04M | 49.72M | 42.41M | 37.76M |
| Gross Profit | 30.98M | 30.98M | 30.99M | 26.07M | 21.59M | 19.32M |
| EBITDA | 3.98M | 3.98M | 2.96M | 2.79M | -5.05M | 3.31M |
| Net Income | 214.00K | 214.00K | -1.27M | -338.00K | -6.12M | 1.36M |
Balance Sheet | ||||||
| Total Assets | 56.63M | 56.63M | 54.39M | 40.36M | 41.18M | 41.71M |
| Cash, Cash Equivalents and Short-Term Investments | 6.15M | 6.15M | 2.69M | 1.89M | 3.80M | 7.29M |
| Total Debt | 14.11M | 14.11M | 13.88M | 8.58M | 9.47M | 6.55M |
| Total Liabilities | 33.92M | 33.92M | 32.57M | 22.15M | 22.89M | 18.12M |
| Stockholders Equity | 22.71M | 22.71M | 21.82M | 18.21M | 18.29M | 23.59M |
Cash Flow | ||||||
| Free Cash Flow | 6.42M | 6.42M | 467.00K | -986.00K | -4.36M | 302.00K |
| Operating Cash Flow | 6.61M | 6.61M | 681.00K | 2.00M | 49.00K | 3.29M |
| Investing Cash Flow | -3.90M | -3.90M | -7.37M | -2.99M | -4.41M | -2.98M |
| Financing Cash Flow | 4.26M | 4.26M | 6.10M | -1.49M | -1.00M | 1.61M |
Compumedics Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMP, the sentiment is Negative. The current price of 0.24 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.25, and below the 200-day MA of 0.27, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 49.14 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CMP.
Compumedics Limited Peers Comparison
Overall Rating
AU:RMD84Outperform- AU:CMP58Neutral
AU:EMV50Neutral
AU:SOM50Neutral
AU:4DX45Neutral
AU:HMD41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:RMD | 84Outperform | AUD 46.01B | 20.92 | 25.14% | 0.91% | 1.54% | 4.43% |
| AU:CMP | 58Neutral | AUD 47.94M | 218.18 | 0.93% | ― | 18.54% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:EMV | 50Neutral | AUD 139.67M | -16.46 | -46.84% | ― | ― | 20.40% |
| AU:SOM | 50Neutral | AUD 63.73M | -23.97 | -5.44% | ― | 2.73% | 25.00% |
| AU:4DX | 45Neutral | AUD 1.47B | -6.19 | -288.42% | ― | 20.64% | -457.40% |
| AU:HMD | 41Neutral | AUD 42.87M | -11.83 | -198.77% | ― | -52.35% | 40.38% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:CMP | Compumedics Limited | 0.24 | -0.10 | -28.36% | |
| AU:SOM | Somnomed Limited | 0.29 | -0.57 | -66.28% | |
| AU:HMD | HeraMED Ltd. | 0.04 | 0.00 | 5.71% | |
| AU:EMV | EMvision Medical Devices Ltd. | 1.50 | -0.31 | -17.02% | |
| AU:4DX | 4DMedical Ltd | 2.44 | 0.84 | 52.50% | |
| AU:RMD | Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh | 35.51 | -1.92 | -5.13% |
Compumedics Limited Corporate Events
Compumedics strengthens finance leadership with new CFO and Company Secretary
Compumedics Limited has promoted Deputy Chief Financial Officer Troy Lamb to Chief Financial Officer and Company Secretary, effective 1 November 2026, with responsibility for ASX communications on listing rule matters. Lamb, a Chartered Accountant wi...
Compumedics Shareholders Back Board and Pay at 2026 AGM
Compumedics Limited has reported the results of its 29 October 2026 annual general meeting, where shareholders strongly backed the re-election of director Rod North. The resolution passed comfortably on a poll, with more than 99% of votes cast in fav...
Compumedics posts record FY26 sales and profit recovery
Compumedics Limited reported a record performance for FY26, with sales rising 18.5% to $60.3 million and EBITDA jumping 74% to $5.4 million, returning the company to profitability and generating $6.6 million in cash from operations, up sharply from $...
Compumedics files updated ASX corporate governance statement for FY2026
Compumedics Limited has released its corporate governance statement for the financial year ended 30 June 2026, confirming that the document is current as of 30 September 2026 and has been approved by the board. The statement, available via the compan...
Compumedics Outlines Board-Led Governance Framework for 2026
Compumedics has detailed its corporate governance framework for the year ended 30 June 2026, emphasising a board structure that blends executive and non-executive directors, with a preference for a non-executive majority to enhance independent oversi...
Compumedics sets proxy rules and virtual access for 2026 AGM
Compumedics Limited has outlined detailed instructions for shareholders to submit proxy voting forms ahead of its Annual General Meeting, scheduled for 10:30am AEDT on 29 October 2026 in Abbotsford and via a virtual platform. Shareholders can appoint...
Compumedics Sets Hybrid 2026 AGM With Focus on Governance and Remuneration
Compumedics Limited has convened its 2026 Annual General Meeting as a hybrid event, to be held on 29 October 2026 at its Abbotsford, Victoria headquarters and via the Automic online investor portal, allowing shareholders to watch, listen, vote and as...
Compumedics Sets Hybrid Format for 2026 Annual General Meeting
Compumedics Limited is an Australian company in the medical technology sector, headquartered at Flockhart Street in Abbotsford, Victoria, and maintains a strong shareholder engagement framework, including hybrid physical and virtual meetings. Its ope...
Compumedics posts record FY26 revenue and sharp EBITDA growth on SaaS and MEG gains
Compumedics reported record FY26 revenue of $60.3 million, up 18.5% year on year, with EBITDA jumping 72.1% to $5.4 million, a return to NPAT profitability and operating cash inflow of $6.6 million that materially strengthened its balance sheet. The...
Compumedics Returns to Profit on Record Revenue and MEG-Led Growth
Compumedics reported a strong financial rebound for the year to 30 June 2026, delivering record shipped and invoiced revenue as well as a return to profitability. The group’s earnings before interest, tax, depreciation and amortisation rose sha...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026